Podcasts about Personalized medicine

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show

Show notes: (0:00) Intro (0:41) Who is Dr. Michael Snyder, and what does he do? (3:44) Catching type 2 diabetes early through personal health tracking (5:59) Why knowing your health baseline matters more than one-time scans (8:49) Using smartwatches to detect illness before symptoms (12:02) Tracking health on a budget (17:04) Why glucose monitors may be the most powerful health tool (18:26) Diabetes subtypes and why one diet does not work for everyone (20:57) Figuring out your diabetic type (24:57) Diet and foods for diabetes (31:55) GLP-1 drugs, benefits, risks, and who they help most (40:26) Genetics vs. epigenetics (44:41) Current studies (46:00) DNA sequence and DNA methylation (48:27) Outro   Who is Dr. Michael Snyder?  Michael Snyder, PhD, is a professor at Stanford University School of Medicine, former chair of Genetics, and director of the Stanford Center for Genomics and Personalized Medicine. He is a leader in genomics and personalized health, known for using DNA, blood data, imaging, and wearable devices to track health early and prevent disease. His research focuses on studying people while they are healthy to catch problems before symptoms appear. Dr. Snyder has published hundreds of scientific papers, launched multiple health tech companies, and authored Genomics and Personalized Medicine: What Everyone Needs to Know. His goal is to shift medicine from sick care to true health care.   Connect with Dr. Snyder Website: https://med.stanford.edu/content/sm/snyderlab.html/ Links and Resources: Peak Performance Life - https://buypeakperformance.com/ Peak Performance on Facebook - https://www.facebook.com/livepeakperformance/ Peak Performance on Instagram - https://www.instagram.com/livepeakperformance

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show

In this episode, our guest is Kate Campbell, PharmD, who serves as the Director of Pharmacy at Olympia Pharmacy. She is a proud alumna of the University of Florida, graduating Cum Laude with a bachelor's degree in biology and a doctorate in pharmacy. Dr. Campbell's previous work experiences in retail and hospital pharmacy have led to a passion for whole-person care and preventive medicine, prompting her shift towards compounding. In her pursuit, she has become a certified hormone replacement therapy specialist with a focus on bioidentical hormone replacement therapy for females.In her personal time, Kate loves connecting with her family and friends. She especially enjoys getting out on the water, playing pickleball and trying new restaurants.1. Opening & BackgroundKate, welcome to the show! Can you start by sharing your journey into pharmacy and what ultimately drew you toward compounding and personalized medicine?You've worked in both retail and hospital settings before moving into compounding—what gaps did you notice in traditional pharmacy that compounding helps to fill?How did your education at the University of Florida shape your path and perspective on whole-person care?2. Understanding Compounding & Regulatory LandscapeFor listeners who may not be familiar, can you explain the difference between 503A and 503B compounding pharmacies?What are some of the key compliance and quality distinctions between these two types of operations?Olympia Pharmacy operates under a 503B designation—what advantages does that provide in terms of scalability, safety, and product consistency?How do you see the role of compounding evolving as more patients seek individualized therapies?3. Hormone Replacement & Preventive MedicineYou're a certified hormone replacement therapy specialist, focusing on bioidentical hormones for women. What drew you to that niche?What are some of the biggest misconceptions about bioidentical hormone therapy?How do you personalize treatment for women across different stages of life—perimenopause, menopause, and beyond?What are the key questions women should ask their providers when considering hormone replacement therapy?4. Longevity & Wellness TrendsLongevity is becoming a buzzword in healthcare. From your vantage point, what longevity-focused products or therapies are worth the hype—and which are not?What innovations are you most excited about in the patient wellness space for the upcoming year?How is Olympia Pharmacy staying ahead of emerging trends—whether it's peptides, nootropics, or nutraceuticals?5. GLP-1s and Post-Therapy CareGLP-1 medications like semaglutide and tirzepatide have transformed weight management—but we're seeing challenges after patients discontinue them.What strategies or compounded therapies are helping patients maintain results post-GLP-1 use?How can pharmacists play a role in supporting metabolic health and sustainability beyond the initial weight-loss phase?6. Leadership, Lifestyle & Personal BalanceAs a director and pharmacist, how do you balance the science of pharmacy with the art of patient care?You've mentioned enjoying pickleball, the water, and exploring new restaurants—how do you recharge outside of work?What advice would you give to other pharmacists looking to explore nontraditional or entrepreneurial paths in pharmacy?7. ClosingWhat's next for you and Olympia Pharmacy?How can listeners connect with you or learn more about the services Olympia offers? ★ Support this podcast on Patreon ★

In this Deep Dive episode of The Trip Lab, we unpack hyperlipidemia (high cholesterol) beyond the oversimplified “LDL bad, HDL good” narrative. We also take a clear-eyed look at the most common concerns people have about statins, what the evidence actually shows, and where these medications fit—and don't fit—within a thoughtful, individualized approach to cardiovascular risk.From there, we explore integrative strategies for managing elevated cholesterol and why, for many patients, lifestyle, metabolic health, and inflammation-targeted interventions may be more effective than medications alone.In this episode, we discuss:Why cholesterol is biologically essential and not inherently pathologicalThe limitations of relying on LDL alone to assess cardiovascular riskHow inflammation, insulin resistance, genetics, hormones, and lifestyle influence lipid metabolismWhen elevated cholesterol truly signals disease—and when it may reflect a compensatory or adaptive responseThe role of advanced markers such as ApoB, Lp(a), hsCRP and CAC scoresWhy risk stratification—not fear-based medicine—should guide clinical decision-makingWhat statins can (and cannot do) and we break down the concerns people have with themWhy integrative approaches (nutrition, exercise, herbal options and mind-body medicine) truly treat the root cause of diseaseThis episode is for clinicians, patients, and anyone looking to move beyond simplistic cholesterol narratives toward a more nuanced, evidence-based understanding of cardiovascular health.

Pharma Influence & Why Patient Voices Matter Lobbying Power: Eli Lilly, Novo Nordisk, and Government Access Why GLP-1 Medication Access Is at Risk Introducing Sabina Hemi & the Mission of GLP Winner Why Compounded GLP-1s Matter for Real Patients The Federal “Safe Drugs” Bill: What It Claims vs What It Does Why This Bill Raises Red Flags for Patients What Real Compounding Safety Reform Would Look Like How Compounding Pharmacies Are Actually Regulated Today Prescription Reporting vs Patient Safety Is This Bill About Safety or Litigation Data? Dose Flexibility, Personalized Medicine, and Compounding Florida SB 860: A Direct Threat to Compounded GLP-1s Why Florida Compounding Impacts the Entire Country Why Obesity Medications Are Being Singled Out Active Pharmaceutical Ingredients (API): What Patients Should Know FDA Oversight, the “Green List,” and State Overreach Why Florida's API & COA Requirements Don't Add Up FDA Inspection Backlogs & Impossible Compliance Standards Branded Drug Safety Issues vs Compounding Scrutiny Catalent, Novo Nordisk, and Manufacturing Concerns Counterfeit Ozempic: The Overlooked Safety Crisis Why Supply Chain Integrity Should Be the Priority What Patients Can Do Right Now Petitions, Advocacy, and Making Your Voice Heard Florida Residents: Why Local Action Matters Final Thoughts on Access, Power, and Patient Advocacy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

https://funmedinstitute.com

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Kashif Khan discuss the intersection of genetics, health, and longevity. Kashif shares his personal journey from illness to founding the DNA company, emphasizing the importance of personalized medicine and genetic testing. They explore the unique health challenges faced by women, the impact of trauma and stress on health, and the need for individualized approaches in biohacking. The conversation highlights the significance of understanding hormone metabolism and the role of genetics in parenting, ultimately advocating for a comprehensive analysis of health to achieve optimal outcomes.   For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways ·        Genetics play a crucial role in understanding individual health. ·        Personalized medicine is essential for effective treatment. ·        Women face unique health challenges that are often overlooked. ·        Understanding hormone metabolism is key to preventing health issues. ·        Trauma and stress can significantly impact health outcomes. ·        Biohacking should be individualized, not one-size-fits-all. ·        Nervous system regulation is vital for overall health. ·        Genetic predispositions can reveal superpowers and vulnerabilities. ·        Parenting can be enhanced through understanding children's genetics. ·        Comprehensive analysis is necessary for accurate health assessments.     Chapters 00:00 Introduction to Kashif and His Journey 05:37 The Role of Genetics in Health 08:12 Understanding Individual Health Through Multiple Lenses 11:12 The Importance of Personalized Medicine 14:00 The Intersection of Genetics and Trauma 17:04 Navigating the Biohacking Landscape 19:54 The Impact of Stress and Anxiety on Health 22:59 Transforming Trauma into Superpowers 29:04 The Impact of Social Media on Identity 30:01 Understanding Genetic Potential in Children 32:32 Personalized Parenting Through Genetic Insights 38:39 Women's Health: A Neglected Area 41:25 Hormonal Health and Cancer Risks 47:32 The Precision of Hormonal Treatments   To learn more about Kashif: Email:  kash@kashkhanofficial.com Website: https://kashkhanofficial.com/   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comTO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comFollow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Dr. Nick and Leah WilsonDr. Nick and Leah WilsonWEBSITE: www.StandForHealthFreedom.com WEBSITE: www.StandForHealthFreedom.comwww.StandForHealthFreedom.com BOOK: https://a.co/d/d9dbqTh BOOK: https://a.co/d/d9dbqThhttps://a.co/d/d9dbqTh Dr. Nick Wilson is a chiropractor, wellness expert, and leading voice in the movement to exit conventional medicine and return to principles of natural health, vitality, and personal responsSend us a message... we can't reply, but we read them all!Support the show► ReAwaken America- text the word FLYOVER to 918-851-0102 (Message and data rates may apply. Terms/privacy: 40509-info.com) ► Kirk Elliott PHD - http://FlyoverGold.com ► My Pillow - https://MyPillow.com/Flyover ► ALL LINKS: https://sociatap.com/FlyoverConservatives

Welcome to Episode 284 of Autism Parenting Secrets.If you've been listening for a while, you know I talk a lot about personalized support — not as a slogan, but because it truly changes outcomes for parents.I used to believe I had to figure everything out alone. I thought muscling through was strength.But that approach made everything heavier, slower, and far more painful than it needed to be.In this episode, I break down why going it alone holds parents back — and why expanding your vision and getting supported helps you move forward faster and with far less weight on your shoulders.The secret this week is…You DON'T Have To Carry It AllYou'll Discover:Why Lowering Your Expectations Quietly Slows Progress (1:05)The Hidden Trap Of “Lesser Goals” And How It Shows Up (2:10)How The Caddy Analogy Reveals What Parents Are Missing (3:45)The Hypocrisy Trap And Why Alignment Changes Everything (5:00)What Happened In The Twins Study And Why It Matters For Your Family (9:45)References In This Episode:Start TodayAutism Parenting Secrets: Episode 220 - Parent Coaching Is the CatalystReversal of Autism Symptoms among Dizygotic Twins through a Personalized Lifestyle and Environmental Modification Approach: A Case Report and Review of the Literature, The Journal of Personalized Medicine, Volume 14, Issue 6Additional Resources:To learn more about personalized 1:1 support, go to www.elevatehowyounavigate.comTake The Quiz: What's YOUR Top Autism Parenting Blindspot?If you enjoyed this episode, share it with your friends.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com The path to truly personalized, affordable medicine runs through data-driven operations, mature software, and disciplined execution. In this episode, Patrick Schinzel, Chief Operating Officer of Strive Pharmacy, shares his first-time HLTH insights and explores how Strive's nationwide compounding model delivers precision therapies with both speed and scale. He explains how a cash-pay pricing strategy broadens access, even as challenges remain for Medicaid and Medicare populations. From the operator's seat, Patrick highlights how analytics aligned clinical freedom with operational efficiency, out of 370 testosterone-boosting combinations, data revealed five consistently effective SKUs that improved delivery times, reduced costs, and enhanced outcomes without limiting physicians. He also details proactive potency testing on sterile lines to ensure efficacy, describes the shift from bespoke precision to “preferred” formulations for scalable personalization, and predicts that maturing software and robotics will soon make “lot size of one” production a reality. Tune in and discover how data, software, and intelligent operations are transforming personalized medicine into scalable, affordable care! Resources: Connect with and follow Patrick Schinzel on LinkedIn. Follow Strive Pharmacy on LinkedIn and visit their website! Email Patrick here.

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

What can I do about a hip labrum tear?Are there any specific water filters that you recommend?What say you about lead levels in dark chocolate?

Soup in cold weatherStudy: No benefit from beta-blockers post heart attack, but vitamin D cuts risk of 2nd heart attack in half!New study links oxalic acid to gadolinium side effects and toxicityMore on the assault on young people's brains

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

In this illuminating episode of Keeping Abreast, Dr. Jenn Simmons sits down with Dr. Taz Bhatia, board-certified physician, integrative medicine pioneer, and champion for women's health, to explore the intricate world of hormones through every season of a woman's life.Dr. Taz shares her personal hormonal journey, the gaps she witnessed in conventional medicine, and why personalized, root-cause driven care is essential. Together, she and Dr. Jenn break down how birth control, stress, gut health, and generational patterns shape hormonal balance. They also dive into innovative diagnostic approaches, including the auria test, and discuss why hormones are often misunderstood, and mismanaged, in modern medical systems.This conversation empowers women to understand their physiology, challenge outdated narratives, and take an active role in their health across puberty, fertility, perimenopause, and beyond.In This Episode, You Will Learn:Why hormonal changes form a lifelong continuumHow birth control can mask deeper imbalancesThe role of gut health and liver detoxification in hormone balanceWhy progesterone deficiency is so common todayHow stress and cortisol impact young women's hormonesThe importance of personalized hormone therapyWhy patients must advocate for their own healthHow hormonal patterns can be passed through generationsWhy breast cancer is often linked to hormone deficiency, not excessHow innovative tools like the auria test may revolutionize screeningEpisode Timeline Highlights:00:00 Introduction & Dr. Taz's personal hormonal journey 02:45 Why traditional hormonal treatments fall short 06:02 How experience reshaped her integrative practice 09:06 Birth control concerns & long-term impacts 11:57 How hormonal suppression affects whole-body health 14:58 The value of holistic, root-cause approaches 17:53 Cultural resistance to new medical paradigms 20:57 Innovations in breast cancer screening (auria test) 23:50 Why change is so hard in established medicine 27:00 Understanding hormonal patterns & testing 29:51 The need for comprehensive hormone education 33:39 Hormonal shifts from puberty to menopause 43:53 Personalized hormone therapy done right 01:01:29 Gut health, the microbiome & hormonal balance 01:04:47 Empowering patients to own their health journeyWhere to find Dr. Taz Bhatia:Website: holplus.coSocial: @DrTazMDTo talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.realhealthmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

About Patrick Schinzel:Patrick Schinzel is the Chief Operations Officer at Strive Pharmacy, where he has been instrumental in driving operational excellence and patient-focused innovation since 2023. With over two decades of experience in pharmacy leadership, Patrick brings a deep understanding of both clinical care and business strategy. Before stepping into his current executive role, he served as a pharmacist at Strive Pharmacy and Walgreens, where he spent nearly 20 years ensuring top-quality patient care and operational efficiency. Beyond pharmacy, Patrick has also demonstrated entrepreneurial drive as the long-time owner of Potential Home Buyers LLC, a real estate venture he has led since 2008. He earned his PharmD and bachelor's in pharmaceutical sciences from South Dakota State University, following his studies at the University of Nebraska–Lincoln and Clarke Community. Based in Mesa, Arizona, Patrick combines his expertise in healthcare and business to advance Strive Pharmacy's mission of delivering accessible, personalized, and high-quality pharmaceutical care.Things You'll Learn:Usage analytics revealed five consistently effective testosterone formulations from 370 variations, enabling faster fulfillment, lower prices, and maintained clinical autonomy.A thoughtful cash-pay strategy can enhance affordability today, even as broader reimbursement for underserved populations remains a significant industry challenge.Proactive potency testing on sterile lines (including GLP-1s) goes beyond basic safety to verify therapeutic effectiveness.“Preferred” formulations can coexist with precision medicine, extracting bulk efficiencies without eliminating personalization.The next leap is software that coordinates interdepartmental nuance, paving the way for robotics to deliver true “lot size of one” at scale.Resources:Connect with and follow Patrick Schinzel on LinkedIn.Follow Clinical Architecture on LinkedIn and visit their website. Email Patrick here.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., this new approach is set to revolutionize personalized medicine, particularly for genetic disorders where tailored interventions are crucial. Gene editing technologies, like CRISPR-Cas9, have opened unprecedented avenues for addressing genetic conditions directly at their source. However, the regulatory framework has struggled to keep pace with these advances, often hampering innovation with lengthy and complex approval processes.This proposed pathway seeks to streamline these requirements by adopting a risk-based assessment model that considers the unique properties of gene-editing therapies. Unlike traditional drugs, which follow a uniform clinical trial path, gene-editing treatments require a more nuanced regulatory approach due to their precision and potential off-target effects. The framework emphasizes adaptive trial designs—allowing for modifications based on interim results—and integrates real-world data to create a dynamic regulatory process. This not only promises faster development times but also fosters innovation by making it easier for companies to bring cutting-edge therapies to market.The implications are far-reaching. For researchers and biotech firms, this represents a chance to reduce time-to-market significantly while maintaining high safety standards. It also sets a precedent for future regulatory models that prioritize patient-centric approaches, acknowledging the diverse genetic landscapes of individuals with rare diseases. On a broader scale, this shift underscores the increasing recognition of personalized medicine's potential to transform healthcare delivery.In parallel developments, Gilead Sciences has achieved positive phase 3 results for its single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. This milestone offers hope for simplifying treatment protocols for patients currently on multi-tablet regimens, potentially enhancing adherence and improving health outcomes. Gilead's preparation for regulatory filings marks an essential step forward in their therapeutic portfolio.Turning to cancer treatment advancements, Kyowa Kirin's collaboration with Kura Oncology has led to FDA approval for an oral medication targeting a subset of acute myeloid leukemia patients. This approval highlights the power of strategic partnerships in expediting the development of targeted cancer therapies and brings new hope to patients with limited treatment options.Meanwhile, several pharmaceutical companies, including Fresenius, Sun Pharma, and Teva, have been involved in product recalls ranging from hospital drugs to antibiotics and ADHD medications. These recalls underscore ongoing challenges in maintaining drug safety standards and emphasize the need for rigorous quality control measures across the industry.Zealand Pharma has opted to pause development of its dual GLP-1/GLP-2 agonist, dapiglutide, due to an increasingly crowded metabolic disorder treatment landscape. By reallocating resources towards programs with greater clinical differentiation potential, Zealand reflects broader industry trends prioritizing investments in areas with clearer paths to market success.In malaria treatment advances, Novartis has achieved significant progress with its next-generation drug 'Ganlum,Support the show

Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance, discusses the importance of targeted nutrients for women's health. They delve into various supplements such as magnesium, myo-inositol, progesterone cream, D-Mannose, and biotin, explaining their benefits for conditions like PCOS, blood sugar regulation, menstrual migraines, urinary tract infections, and overall skin, hair, and nail health. The conversation also touches on the importance of tailoring nutrients to individual needs and the role of personalized nutrition in supporting women's health amidst modern stresses.

Dr. Hoffman continues his conversation with Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance.

In this deeply inspiring episode of Keeping Abreast, Dr. Jenn Simmons welcomes Dr. Pete Sulack—chiropractor, functional medicine practitioner, and founder of Unhealthy Anonymous—for a powerful conversation about defying the odds after a terminal cancer diagnosis.Dr. Sulack shares how he turned a death sentence into a journey of hope, healing, and renewal. Through faith, nutrition, and lifestyle transformation, he reclaimed his health and now guides others to do the same. Together, he and Dr. Jenn challenge conventional cancer paradigms, exploring how mindset, personalized nutrition, and spiritual alignment can unlock the body's innate capacity to heal.This episode invites listeners to rethink what's possible in cancer recovery and beyond. It's a story of courage, resilience, and faith in both science and spirit—reminding us that health is not something we outsource but something we build from within.In This Episode, You Will Learn:How Dr. Sulack overcame a terminal brain cancer diagnosisWhy functional medicine focuses on healing the whole person, not just treating diseaseThe crucial role of personalized nutrition in recoveryHow food sensitivities and gut health shape overall wellnessWhy conventional medicine often overlooks the importance of dietThe link between faith, mindset, and the body's innate ability to healHow to take proactive responsibility for your healthWhy empowerment and education can change the cancer care paradigm

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, China has approved its first EGFR-targeted antibody-drug conjugate. This approval marks a pivotal moment in the industry's shift towards targeted therapies, which promise more precise treatment options with potentially fewer side effects than traditional chemotherapy. Targeted therapies are at the forefront of personalized medicine, where treatments are tailored to individual genetic profiles, offering hope for more effective cancer care.In the realm of HIV prevention, Gilead Sciences has reported impressive sales for its new long-acting pre-exposure prophylaxis medication, Yetztugo. Since its launch in June 2025, Yetztugo has generated $54 million in U.S. sales, underscoring the demand for long-term HIV prevention solutions. This development is part of Gilead's broader strategy to strengthen its HIV franchise as it advances its pipeline with promising candidates like GS-3242 alongside lenacapavir. The aim is to develop treatments that require less frequent dosing, which could significantly improve patient adherence and outcomes. Despite challenges within its HIV portfolio and declining Veklury sales, Gilead Sciences is actively seeking growth opportunities through strategic partnerships and pipeline advancements—an essential approach for navigating patent cliffs while sustaining long-term growth.On the financial front, AbbVie has increased its revenue forecast by $400 million to a staggering $60.9 billion, driven by robust sales from its immunology drugs Skyrizi and Rinvoq. These treatments address chronic inflammatory conditions like psoriasis and rheumatoid arthritis, reflecting AbbVie's strong positioning in this therapeutic area despite competitive pressures. AbbVie continues to report strong earnings from Skyrizi and Rinvoq, reinforcing its dominance in the immunology market and highlighting the profitable nature of successful biologics in treating chronic inflammatory diseases.Biogen continues to bolster its multiple sclerosis franchise by focusing on both legacy treatments and new product launches. This strategy highlights the importance of balancing innovation with lifecycle management to maintain market strength against generic competition—a common challenge in the industry.Meanwhile, the American Academy of Pediatrics has taken a cautious stance by not endorsing leucovorin for autism treatment due to insufficient evidence. This decision emphasizes the critical need for rigorous, evidence-based practices in developing clinical guidelines for complex disorders like autism.Internationally, CSL Seqirus has partnered with Saudi Arabia to supply cell-based influenza vaccines and support local production capabilities. This move aligns with global efforts to enhance pandemic preparedness and healthcare resilience through local manufacturing initiatives.The volatile nature of the biotech sector is evident with reports of 16 companies ceasing operations in 2025 due to high R&D costs and regulatory challenges. Despite these closures, such volatility opens doors for new innovations that could address unmet medical needs.Turning our attention to obesity treatment, Eli Lilly stands at a crucial juncture with its novel obesity medication, orforglipron. The company aims to make this weight loss pill accessible while maintaining financial viability for future R&D—a balancing act faced by many pharmaceutical companies as they strive to deliver affordable yet innovative treatments amid growing global health concerns. However, not all R&D efforts reach fruition. Eli Lilly has decided to discontinue its mid-stage program Support the show

In this episode, Dr. Jockers talks with Dr. Joel Warsh about what doctors aren't taught about vaccines in medical school and why long-term safety research is still missing. They explore how the rise in chronic illness among kids might connect to current vaccine practices. Dr. Warsh explains why asking hard questions isn't being "anti-science" — it's how we make medicine safer. He shares why vaccine schedules should be personalized and how real informed consent helps parents make better choices. Together, they break down what's actually in vaccines, how they're tested, and why open, honest conversations about health are long overdue. In This Episode: 00:00 Introduction: Vaccine Safety Concerns 02:38 Interview Introduction: Dr. Joel Warsh 02:51 The Chronic Disease Epidemic in Children 04:06 Personal Stance on Vaccination 06:33 The Rise of Chronic Diseases in Children 08:28 Factors Contributing to Chronic Diseases 09:50 Political and Environmental Influences on Health 17:30 The Role of Medications in Modern Health 19:29 Medical Training and Nutrition 23:59 Historical Context of Vaccines 30:32 How Vaccines Work and Personalized Medicine 33:59 Exploring Vaccine Reactions and Genetic Testing 36:38 The Controversy Surrounding Hepatitis B Vaccine 41:21 Questioning Vaccine Safety and Placebo Studies 45:42 Concerns About Vaccine Ingredients 59:33 The Need for Better Vaccines and Open Discussion 01:03:58 Conclusion and Final Thoughts If you want a nutrient-packed boost, check out Paleo Valley's Grass-Fed Organ Complex—a supercharged multivitamin containing liver, heart, and kidney from healthy pasture-raised cows. It delivers a full spectrum of B vitamins, minerals, amino acids, and peptides without the strong taste of organ meat. For a 15% discount, visit paleovalley.com/jockers and stock up on this powerful supplement to support energy, mental clarity, and overall health. Looking to boost your digestion, immunity, and energy? Just Thrive Probiotic is the answer! Unlike most probiotics that get destroyed by stomach acid, Just Thrive is clinically proven to reach your gut 100% alive. This means better digestion, improved immunity, enhanced energy, and easier weight management. Plus, with their industry-leading 100% money-back guarantee, you've got nothing to lose. Save 20% off your order with code JOCKERS at justthrivehealth.com. "It's not about whether vaccines are good or bad, but about creating a system that better assesses their long-term safety and impacts." Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio Resources: Get 15% off Paleovalley: paleovalley.com/jockers – Use code JOCKERS Save 20% on Just Thrive: justthrivehealth.com – Use code JOCKERS Connect with Dr. Joel Warsh: Website: https://integrativepediatrics.com/ Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https:/www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/

Dr. Hoffman continues his conversation with Dr. Alexandra Shustina, NYC's and Miami's premier Integrative board-certified Gastroenterologist and gut health specialist, an expert in the gut microbiome and its role in health and wellness.

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman is joined by Dr. Alexandra Shustina, a distinguished integrative gastroenterologist based in New York City and Miami. They delve into Dr. Shustina's journey from conventional to integrative medicine, the importance of addressing the microbiome, and holistic approaches to treating gastrointestinal ailments like IBS, Crohn's disease, and ulcerative colitis. Dr. Shustina shares her insights on diet, the impact of stress, and the role of supplements and herbal remedies. She discusses the significance of personalized care, visceral manipulation, and mind-body techniques in promoting gut health. The episode also touches on the rising incidence of gastrointestinal cancers in young people and the potential benefits of proactive, integrative healthcare approaches.

Many patients have questions on the use of peptides. What are peptides and what are the most common peptides used as well as the safety and other concerns. BPC157 is one of the most common peptides that patients ask about. There are more but today, Ray Solano of PD Labs and I discussed peptide use and safety. Chapters: 0:00

With a calcium score of zero, is there any fat in your diet?  Are there any recommended supplements for IBS?What is the safest and most appropriate dose of vitamin D3 for most seniors?

INFINITY Study on the timing of thyroid medication ingestionI have a growth near my eye that is changing in color and becoming crusty. What should I do?I've been suffering from hip pain for the last three years. Any suggestions on what to do?Could toxic exposures like mold cause conditions like low thyroid or autoimmunity?

Many challenging medical conditions defy treatment and challenge clinicians to come up with innovative solutions—Chronic Fatigue Syndrome, fibromyalgia, Lyme Disease, Multiple Chemical Sensitivity (MCS), Ehlers-Danlos Syndrome (EDS) and autoimmune conditions; add now the growing burden of patients with Long Covid and vaccine injury. Dr. Tania Dempsey specializes in treating these complicated chronic disorders. She has embraced and advanced a new paradigm based on addressing Mast Cell Activation Syndrome (MCAS). What is MCAS? How is it differentiated from ordinary allergies, and why are its symptoms so pervasive? What are its causes and triggers? What role for low-histamine diets? Antihistamines? Other novel medications? What nutritional supplements can facilitate its resolution? How does recognition of the contribution of MCAS facilitate treatment of patients suffering from Long Covid and vaccine injuries?

Dr. Hoffman continues his conversation with Dr. Tania Dempsey.

In this episode of the Shift AI Podcast, Vik Bajaj, CEO and Co-founder of Foresite Labs and Interim President at Xaira Therapeutics, joins host Boaz Ashkenazy to explore how AI is revolutionizing life sciences and healthcare. With a distinguished background spanning physics, structural biology, radiology at Stanford, and pioneering work at Google, Vik brings a unique perspective on the intersection of AI and medicine.The conversation delves into the stark realities of drug discovery—where 2 million researchers globally struggle against success rates so low that most will be lucky to contribute to one or two successful drugs in their entire careers. Vik explains how AI, particularly David Baker's groundbreaking protein design work, is poised to transform this landscape by enabling drugs for previously "undruggable" targets and moving healthcare from reactive treatment to predictive, personalized medicine.From genetic tests that could provide actionable insights for 75% of people to AI models that can predict 5-year mortality from a simple chest X-ray, this episode reveals how we're approaching a future where disease prevention replaces disease treatment. If you're interested in understanding how AI will fundamentally reshape healthcare economics and why Vik compares this transformation to the industrial revolution, this episode is essential listening.Chapters: [01:48] From Physics to Life Sciences: Vik's Interdisciplinary Journey [04:13] The Google Years: Early AI Revolution in Science [06:56] Xaira Therapeutics and David Baker's Protein Design Breakthrough [09:28] The Optimistic Future of AI in Drug Discovery [15:17] The Four-Stage Evolution of AI in Medicine [19:53] Healthcare Cost Crisis and AI Solutions [23:27] The Promise of Personalized Medicine [28:39] Foresite Labs: Specializing in Science and Engineering AI [32:00] Why Healthcare AI is Harder Than Software Engineering [36:27] Two Words for the Future: Industrial RevolutionContact Info:Connect with Vik Bajaj● LinkedIn: https://www.linkedin.com/in/drvikbajaj/ Connect with Boaz Ashkenazy● LinkedIn: https://www.linkedin.com/in/boazashkenazy● X: boazashkenazy● Email: info@shiftai.fm

Love the episode? Send us a text!What if your cancer treatment was designed just for you?In this episode of Breast Cancer Conversations, host Dr. Laura Carfang sits down with Jim Foote, CEO and co-founder of First Ascent Biomedical, to explore how AI-powered functional precision medicine is transforming cancer care.Instead of relying on one-size-fits-all treatment plans, this breakthrough approach tests your actual tumor cells against hundreds of FDA-approved drugs—revealing which therapies truly work for you and which don't.

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Europe: Bettina Ryll: Stockholm School of Economics, Institute for Research; Founder, Melanoma Patient Network Europe. Kjetil Taskén: Head of the Institute for Cancer Research, Oslo University Hospital; Professor, University of Oslo; Coordinator, PRIME-ROSE. Anni Lepland: Head of Personalized Medicine in Oncology, Estonian Cancer Network. They explore how Europe’s new Joint Action can accelerate equitable precision oncology, what PRIME-ROSE has learned from aggregating data across national pragmatic trials, and why a distributed, bottom-up model with strong patient involvement and industry collaboration is key to scaling access and evidence generation across member states. Key Topics: EU Joint Action: Governmental collaboration, precision prevention, diagnosis, and treatment, precision follow-up. PRIME-ROSE Collaboration: Data sharing agreements, aggregated cohorts, common biomarker definitions, and monthly alignment. Patient Need First: Options after standard care, access to molecular profiling, pragmatic protocols, and learning from each case. Widening Country Gaps: Workforce shortages, national coordination, digital tools, and equitable access to innovative drugs. Industry and Access: Single point of entry for drugs, managed entry agreements, off-label registries, and scaling trials across Europe. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

In this eye-opening episode of the Healthy & Awake Podcast, Dr. John Catanzaro joins Mike Vera to break down 12 of the most searched alternative and integrative cancer treatments. From ivermectin, fenbendazole, and methylene blue, to peptides, vitamin C, cannabis, DMSO, and more—Dr. Catanzaro explains what actually works, what's promising, and what's overhyped. They also dive into the role of the microbiome, mitochondria, spike protein, and lifestyle changes in cancer progression and recovery. If you or someone you know is exploring options beyond conventional cancer care, this episode is a must-listen.https://neo7bioscience.com/___________________________

In this episode of Disruption/Interruption, host KJ sits down with Jim Foote, CEO and founder of First Ascent Biomedical. Jim shares his personal journey from technology executive to cancer care innovator, after his son’s diagnosis changed his life. Discover how he’s disrupting the status quo in oncology with AI-driven, personalized medicine that’s giving new hope to patients and families. Key Takeaways: The Problem with Standard Cancer Care [3:53]The standard of care treats patients as if they are the same, but everyone is unique. This approach works two-thirds of the time, but leaves one-third of patients with few options. Functional Precision Medicine [13:04]Jim’s company tests up to 152 FDA-approved drugs on a patient’s biopsy to find the most effective treatment, providing doctors with data-driven options tailored to each individual. AI and Technology are Transforming Oncology [28:05]Advances in AI, robotics, and cloud computing have converged, making personalized cancer treatment faster, more affordable, and more effective than ever before. Impact and Future Vision [26:51]Jim’s goal is for every cancer patient to receive individualized treatment from the moment of diagnosis, improving outcomes and reducing unnecessary side effects. Quote of the Show (14:40):“I literally have gone from trying and hoping to testing and choosing.” — Jim Foote Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jim Foote: LinkedIn: http://www.linkedin.com/in/jim-foote Company Website: https://firstascentbiomedical.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

otplinks.com stallybrand.com (code OTP10) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Glowing Older podcast, host NancyGriffin interviews Susie Ellis, Chair, CEO, and Co-Founder of the Global Wellness Summit and the Global Wellness Institute. They discuss the evolution of wellness, the importance of healthspan over lifespan, and the role of research in defining wellness. Susie shares insights on the history of the Global Wellness Summit's, the nonprofit initiatives, and the significance of social connections in wellness. The conversation also touches on biohackingtrends, self-care for aging well, and the future of wellness and longevity.About SusieSusie Ellis is the chair and CEO of the nonprofit Global Wellness Institute, considered the industry's leading global research and educational resource. She is also chair and CEO of the Global Wellness Summit, an organization at the heart of the multi-trillion-dollar global wellness economy focused on facilitating collaboration amongst industry thought leaders. Recognized as a leading authority on wellness trends, shesits on numerous academic and industry boards, including the EHL Hospitality Business School in Lausanne, the Penn Center for Neuroaesthetics, and was also a member of the World Economic Forum's “Accelerating Health and Well-being Initiative.” She holds an MBA from the University of California, Los Angeles.Key TakeawaysThe Global Wellness Institute provides wellness research at no cost. Research is crucial for defining and understanding wellness and longevity.The Global Wellness Institute defines 11 sectors of the $6.3 trillion dollar wellness economy: Wellness Real Estate; Physical Activity; Healthy Eating, Nutrition and Weight Loss; Public Health, Prevention, and Personalized Medicine; Traditional and Complementary Medicine; Personal Care andBeauty; Wellness Tourism; Spa Economy; Thermal and Mineral Springs; Workplace Wellness; Mental Wellness. The medical community is more interested in wellness post COVID. There is more research and science showing valuable steps that people can take to improve their health.Wellness modalities are the cornerstone of longevity. What contributes to wellness also contributes to longevity.

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

Dr. Ravi Kamepalli made a startling realization that changed everything: bacteria aren't the enemy. As both an infectious disease specialist and wound care physician, he witnessed firsthand how traditional medicine's war on microbes was failing patients catastrophically. In this profound conversation, he unveils his revolutionary "disease triangles" framework that connects our immune system, lipid metabolism, and microbiome in ways that transform how we understand healing.The statistics he shares will shock you: diabetic foot amputations have a higher five-year mortality rate than breast cancer. While diabetes costs healthcare systems $237 billion annually compared to cancer's $80 billion, we're attacking symptoms instead of root causes. Dr. Kamepalli explains his concept of "energy toxicity" - how excess stored energy triggers inflammatory cascades that turn our own immune systems against us.Through his personal journey of losing 50 pounds and dramatically reducing his LP(a) levels, he demonstrates that supposedly "genetic" markers are actually nutritionally modifiable. His approach integrates metabolic interventions with wound care, using continuous glucose monitoring, food logging, and remote patient tracking to address the underlying metabolic dysfunction that prevents healing.This isn't just about wound care - it's about reimagining medicine itself. Dr. Kamepalli advocates for moving beyond "mass medicine mindset" toward personalized, n-of-one healthcare that empowers patients with tools, tracking, and understanding rather than simply prescribing interventions. His vision extends from revolutionizing American healthcare to building sustainable systems in rural India.BIG IDEA"We cannot kill bacteria and keep the humans alive - we need to learn how to survive together, and that survival depends on fixing our metabolic dysfunction, not declaring war on microbes."Dr. Ravi Kamepalli Contact InfoWebsite: https://nobadbugs.com/Social Media: @WoundPhysicianWebsite: ColigoMed.comSociety for Metabolic Health Practitioners SMHP.orgSend Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

In this episode of It Happened To Me, we share a story of love, loss, and advocacy in the rare disease community. We are joined by Jordan Kruse, whose son, Pruitt, was born with ornithine transcarbamylase (OTC) deficiency, and Dr. Susan Berry, a geneticist at M Health Fairview and professor at the University of Minnesota Medical School, who specializes in rare metabolic disorders like OTC deficiency and helped Pruitt.  OTC deficiency is a rare urea cycle disorder (UCD) that prevents the body from properly removing ammonia from the blood. This dangerous buildup can cause severe complications, and in Pruitt's case, tragically ended his life at only six months old.  Through her grief, Jordan founded The Brave Little One Foundation, honoring Pruitt's legacy by supporting families facing medical hardship and raising awareness about rare genetic conditions. Together, she and Dr. Berry shed light on: What OTC deficiency is and how it affects the body Why newborn screening doesn't always catch the condition The role of geneticists and medications in diagnosing and managing OTC deficiency Jordan's experience advocating for Pruitt's care in a complex medical system The importance of foundations and rare disease organizations in offering resources and hope What families and healthcare providers need to know about navigating rare disease diagnoses Resources: The Brave Little One Foundation National Urea Cycle Disorders Foundation (NUCDF)  The Rare Diseases Clinical Research Network (RDCRN Consortia) The Future of Personalized Medicine is Here: Baby KJ received a first-of-its-kind personalized gene editing therapy at CHOP to treat his urea cycle disorder Ornithine transcarbamylase deficiency explained by MedlinePlus    Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

Support the Institute today. https://www.nova.edu/give/index.html?area=Institute%20for%20Neuro-Immune%20Medicine&designation=INIM%20Grateful%20Patient%20Fund   Showing empathy to patients and truly being in their shoes is how we begin to redefine care. Today, Haylie Pomroy is joined by Nurse Practitioner Irina Rozenfeld to talk about how personalized care for chronic illness can help improve and redefine the way we approach healthcare today. Dr. Rozenfeld shares her formula for helping patients gain access to adequate care, the role of empathy in building strong therapeutic relationships, and how her advocacy work also empowers patients to become advocates for themselves. Together, they dig deep into personalized medicine, the impact of knowledge deficit in healthcare, and how a patient can more effectively communicate with their practitioner to achieve the best outcomes. Learn more on the Hope and Help for Fatigue and Chronic Illness Podcast: Redefining Care: Personalized Medicine for Chronic Illness   Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others. You can also catch this show on YouTube and other podcast platforms.    Sign up for the COVID-UPP Study: https://redcap.nova.edu/redcap/surveys/?s=RMEDJ7LKCX&_gl=1*1h830h7*_gcl_au*MTM2NDA0MTQyOS4xNzE1MDA0ODAy   If you are interested in joining a Gulf War Illness (GWI) trial, please complete the Recruitment Registry Form. https://redcap.nova.edu/redcap/surveys/?s=Y9YF8JJWJRK8HEKL%20&_gl=1*1fipp18*_gcl_aw*R0NMLjE3MDc5MTgwMzIuRUFJYUlRb2JDaE1JeWNyUXVfcXFoQU1WU1pCYUJSM3AyQWRBRUFBWUFTQUFFZ0s1NWZEX0J3RQ..*_gcl_au*MTg2NjgwMDQ4Ni4xNzA3MTQwNzgx   Irina Rozenfeld, DNP, MSHS, APRN, ANP-BC is is a Board Certified Nurse Practitioner committed to the health of her patients. Irina emphasizes patient-practitioner relationships, critical thinking, and patient education to develop an optimal treatment plan and achieve sustainable results. She obtained her Bachelor's of Science degree from Nova Southeastern University and a Master's of Science in Nursing Studies from Florida International University. Additionally, she has obtained a Master's degree in Integrative Medicine from George Washington University School of Medicine and a Doctoral degree at the University of North Florida. Before joining the INIM, Irina worked for more than twenty years as a physician assistant in Russia. After relocating to Florida, she worked as a Clinical Research Nurse at Nova Southeastern University. Irina obtained an international certification as a Clinical Research Professional and has been involved in research in many roles. Irina teaches at Nova Southeastern University College of Nursing as an adjunct faculty.   Facebook: https://www.facebook.com/irina.rozenfeld.1  LinkedIn: https://www.linkedin.com/in/irina-rozenfeld-413a4028/  Instagram: https://www.instagram.com/irina.rozenfeld.1/   Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet.   Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com   Instagram: https://www.instagram.com/hayliepomroy Facebook: https://www.facebook.com/hayliepomroy YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy    Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others.   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here. Website: https://www.nova.edu/nim/  Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine  Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Millions of people are living with unexplained symptoms like allergies, brain fog, anxiety, and chronic fatigue without realizing the hidden cause: mast cells gone rogue. In this episode of The Human Upgrade, Host Dave Asprey sits down with leading functional medicine physician Dr. Tania Dempsey to uncover how Mast Cell Activation Syndrome (MCAS) drives inflammation, disrupts mitochondria, and sabotages metabolism—and what you can do to switch it off. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dr. Dempsey is internationally recognized for her work in functional medicine, biohacking, and chronic illness. She co-founded the AIM Center for Personalized Medicine, has published groundbreaking research on MCAS with Dr. Lawrence Afrin, and treats some of the most complex cases of immune dysregulation, autoimmune disease, and environmental illness. Her expertise helps you understand why mast cells are the missing link in allergies, long COVID, Lyme, mold toxicity, and even hormone disruption—and how to reclaim control of your biology. Dave and Dr. Dempsey break down how mast cells interact with mitochondria, hormones, and the nervous system, showing how chronic inflammation accelerates aging and blocks human performance. You'll discover why biohacking tools like fasting, ketosis, supplements, red light, cold therapy, sleep optimization, and smarter not harder lifestyle strategies all influence mast cell stability. They also explore why brain optimization, neuroplasticity, and nootropics are essential for calming inflammatory cascades, and how functional medicine provides practical solutions beyond conventional treatment. You'll Learn: • Why mast cells are the hidden switch behind allergies, chronic inflammation, and brain fog • How mitochondria and mast cells work together to drive human performance—or disease • The connection between toxic mold, Lyme, long COVID, hormone imbalance, and MCAS • How supplements, fasting, ketosis, and cold therapy stabilize mast cells and boost longevity • Why functional medicine and biohacking are essential for complex chronic illness • How mast cells impact metabolism, sleep optimization, and neuroplasticity • The surprising link between mast cells, anxiety, and mental health symptoms This episode is essential for anyone serious about hacking inflammation, protecting longevity, upgrading metabolism, and achieving high performance with resilience and clarity. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting-edge insights in health, performance, neuroscience, supplements, nutrition, hacking, emotional intelligence, and conscious living. Episodes are released every Tuesday, Thursday, and Friday (audio-only) where Dave asks the questions no one else dares, and brings you real tools to become more resilient, aware, and high performing. Keywords: mast cell activation syndrome, MCAS, chronic inflammation, mitochondria dysfunction, histamine intolerance, functional medicine, biohacking, allergies, brain fog, long covid, mold toxicity, Bartonella, Lyme co-infections, oxalates, salicylates, mast cell stabilizers, immune dysregulation, neuroinflammation, chronic fatigue syndrome, autoimmune triggers, personalized medicine, longevity supplements Thank you to our sponsors!Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off.LMNT | Free LMNT Sample Pack with any drink mix purchase by going to https://drinklmnt.com/DAVE.Resources: • Tania's Website: https://drtaniadempsey.com/ • Danger Coffee: https://dangercoffee.com/DAVE15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 00:00 — Trailer 01:10 — Introduction 03:27 — Why So Sick Today? 05:57 — MCAS Explained 08:33 — Mold & Environment 11:36 — Spotting MCAS 13:43 — Personal Stories 15:15 — Research & Biohacking 16:35 — Managing Triggers 20:15 — Gut & Stomach Acid 22:42 — Reaction Timing 25:30 — Hormones & MCAS 28:39 — Thyroid & Mitochondria 32:28 — Chronic Illness Navigation 40:06 — Insurance Battles 44:44 — Cholesterol & Ethics 49:11 — Personalized Care 53:24 — Circadian & Stress 58:24 — Testing Approaches 01:01:35 — Collagen & Joints 01:04:34 — MMPs & Aging 01:09:12 — Access & Experimentation 01:13:14 — MCAS & Mental Health 01:17:46 — Benzos & Stigma 01:20:23 — Vaccines & Spike Protein 01:25:18 — Research & Treatments 01:26:12 — Nicotine & Focus 01:29:24 — Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textCould the opioid crisis be solved through genetic testing? What if doctors could identify your addiction risk before prescribing pain medication? These questions drive the innovative work at Thrive Genetics, where personalized medicine is revolutionizing how we approach pain management and addiction prevention.James Piacentino shares his journey from tech executive to healthcare innovator, motivated by watching his father struggle with alcoholism and prescription drug addiction. This deeply personal mission led him to create a system that combines genetic testing with behavioral analysis to generate comprehensive addiction risk profiles for patients before medical procedures.The science is compelling – addiction typically stems from a 50/50 split between genetic predisposition and behavioral factors. By analyzing both components through a proprietary algorithm, Thrive Genetics helps physicians tailor medication plans based on individual risk profiles. For high-risk patients, alternative approaches might include non-opioid medications or adjusted dosages, potentially saving countless individuals from developing dependencies.We explore the staggering statistics behind the opioid epidemic (Americans consume 99% of global hydrocodone) and discuss how personalized medicine represents a balanced approach that maintains quality care while addressing cost concerns. James walks us through the patient journey – from initial testing to personalized treatment plans – and shares powerful stories illustrating the human impact of addiction and recovery.Our conversation ventures beyond healthcare into profound territory, examining how family trauma shapes us, the nature of self-awareness in recovery, and philosophical questions about purpose and spiritual growth. James offers wisdom from both professional innovation and personal reflection, reminding us that sometimes our deepest wounds become the source of our greatest contributions to others.Connect with Thrive Genetics at thrivegeneticsai.com to learn more about this groundbreaking approach to addiction prevention and personalized medicine.http://www.thrivegenetics.ai/ Support the show https://www.audible.com/pd/9-Simple-Steps-to-Sell-More-ht-Audiobook/B0D4SJYD4Q?source_code=ASSORAP0511160006&share_location=library_overflowhttps://www.amazon.com/Simple-Steps-Sell-More-Stereotypes-ebook/dp/B0BRNSFYG6/ref=sr_1_1?crid=1OSB7HX6FQMHS&keywords=corey+berrier&qid=1674232549&sprefix=%2Caps%2C93&sr=8-1 https://www.linkedin.com/in/coreysalescoach/

In this episode of the Smarter Not Harder Podcast, the HOMeHOPe Faculty comes together for a hilarious and eye-opening roundtable conversation exploring the strangest, funniest, and most surprising health questions they've ever received. From wild patient stories to unexpected clinic confessions, this episode blends humor with real-world medical insight. Join us as we delve into: • The most bizarre patient DMs and clinic questions • Morning wood, priapism, and hormone balancing myths • Emergency room confessions you won't believe • What patients really do (and don't admit) to their doctors This episode is for you if: • You're curious about the funniest moments in medicine • You want to hear health optimization experts unfiltered • You enjoy learning through real patient stories and cases • You like laughing while still picking up practical insights You can also find this episode on… YouTube: https://youtu.be/HR_tgbe4EY0 Find more from Smarter Not Harder: Website: https://www.troscriptions.com/pages/podcast Instagram: https://www.instagram.com/troscriptions HOMeHOPe Symposium: https://homehope.org/homehope-symposium Get 10% Off your purchase of the Metabolomics Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions purchase by using POD10 at https://www.troscriptions.com Get daily content from the hosts of Smarter Not Harder by following @troscriptions on Instagram.